Hypertension and nephropathy

American Journal of Medicine

Volumn 115, Issue 8 SUPPL. 1, 2003, Pages 49-54

  Bakris, George L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIURETIC AGENT; TROGLITAZONE;

ARTERIAL PRESSURE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

EID: 0347480404     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.08.013     Document Type: Conference Paper

References (45)

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 157:1997;2413-2446.
2. Perry H.M. Jr, Miller J.P., Fornoff J.R., et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 25:1995;587-594.
3. Staessen J.A., Wang J.-G., Thijs L. Cardiovascular protection and blood pressure reduction a meta-analysis . Lancet. 358:2001;1305-1315.
4. Coresh J., Wei G.L., McQuillan G., et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States findings from the Third National Health and Nutrition Examination Survey (1998-1994) . Arch Intern Med. 161:2001;1207-1216.
5. Kennedy B.S., Kasl S.V., Brass L.M., Vaccarino V. Trends in hospitalized stroke for blacks and whites in the United States, 1980-1999. Neuroepidemiology. 21:2002;131-141.
6. Morbidity and Mortality: 2002 Chart Book on Cardiovascular, Lung, and Blood Diseases. 2002;1-90 National Institutes of Health, Bethesda, MD.
7. Bakris G.L., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes a consensus approach . Am J Kidney Dis. 36:2000;646-661.
8. Clinical practice recommendations 2003. Diabetes Care. 26:(suppl 1):2003;S1-S144.
9. Campbell N.R.C., Drouin D., Feldman R.D. The 2001 Canadian hypertension recommendations take-home messages . Can Med Assoc J. 167:2002;661-668.
10. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification . Am J Kidney Dis. 39:(suppl 2):2002;S1-S246.
11. Ramsay L., Williams B., Johnston G.D., et al. Guidelines for management of hypertension report of the Third Working Party of the British Hypertension Society . J Hum Hypertens. 13:1999;569-592.
12. Chalmers J. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension guidelines subcommittee . J Hypertens. 17:1999;151-183.
13. Reaven G.M. Diet and syndrome X. Curr Atheroscler Rep. 2:2000;503-507.
14. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . JAMA. 288:2002;2981-2997.
15. Smith A.C., Fogelfeld L., Bakris G.L. New therapies in diabetes thiazolidinediones . Emerging Drugs. 5:2002;441-456.
16. Martens F.M., Visseren F.L., Lemay J., et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 62:2002;1463-1480.
17. Eto K., Ohya Y., Nakamura Y., et al. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol. 423:2001;1-7.
18. Knock G.A., Mishra S.K., Aaronson P.I. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol. 368:1999;103-109.
19. Diep Q.N., El Mabrouk M., Cohn J.S., et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats role of peroxisome proliferator-activated receptor-γ Circulation. 105:2002;2296-2302.
20. Raji A., Seely E.W., Bekins S.A., et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 26:2003;172-178.
21. Buckingham R.E., Al-Barazanji K.A., Toseland C.D., et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 47:1998;1326-1334.
22. Walker A.B., Chattington P.D., Buckingham R.E., Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 48:1999;1448-1453.
23. Iwamoto Y., Kosaka K., Kuzuya T., et al. Effects of troglitazone a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy . Diabetes Care. 19:1996;151-156.
24. Surg B.H., Izzo J.L. Jr, Dandona P., Wilson M.F. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 34:1999;83-88.
25. Ogihara T., Rakugi H., Ikegami H., et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 8:1995;316-320.
26. Reynolds L.R., Konz E.C., Frederich R.C., Anderson J.W. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. Diabetes Obes Metab. 4:2002;270-275.
27. De Gaudio A.R., Adembri C., Grechi S., Novelli G.P. Microalbuminuria as an early index of impairment of glomerular permeability in postoperative septic patients. Intensive Care Med. 26:2000;1364-1368.
28. Diercks G.F.H., van Boven A.J., Hillege H.L., et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population the PREVEND (Prevention of REnal and Vascular ENdstage Disease) study . Eur Heart J. 21:2000;1922-1927.
29. Garg J.P., Bakris G.L. Microalbuminuria marker of vascular dysfunction, risk factor for cardiovascular disease . Vasc Med. 7:2002;35-43.
30. Bakris G.L. Microalbuminuria what is it? Why is it important? What should be done about it? J Clin Hypertens. 3:2001;99-102.
31. Kohler K.A., McClellan W.M., Ziemer D.C., et al. Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. Am J Kidney Dis. 36:2000;903-913.
32. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38 . BMJ. 317:1998;703-713.
33. Ferrannini E., Stern M.P., Galvan A.Q., et al. Impact of associated conditions on glycemic control of NIDDM patients. Diabetes Care. 15:1992;508-514.
34. Levin S.R., Coburn J.W., Abraira C., et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Diabetes Care. 23:2000;1478-1485.
35. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy . Lancet. 355:2000;253-259.
36. Parving H.-H., Lehnert H., Bröchner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 345:2001;870-878.
37. Imano E., Kanda T., Nakatani Y., et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 21:1998;2135-2139.
38. Nakamura T., Ushiyama C., Suzuki S., et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med. 18:2001;308-313.
39. Bakris G., Viberti G., Weston W.M., et al. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens. 17:2003;7-12.
40. Lebovitz H.E., Banerji M.A. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 56:2001;265-294.
41. Lebovitz H.E., Dole J.F., Patwardhan R., et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 86:2001;280-288.
42. Aljada A., Garg R., Ghanim H., et al. Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes evidence of an antiinflammatory action? J Clin Endocrinol Metab. 86:2001;3250-3256.
43. Viberti G., Kahn S.E., Greene D.A., et al. A Diabetes Outcome Progression Trial (ADOPT) an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes . Diabetes Care. 25:2002;1737-1743.
44. McMaster research team awarded $25 million for diabetes clinical trial [press release]. Hamilton, Ontario, Canada: McMaster University Health Sciences; November 1, 2000. Available at: http://www.fhs.mcmaster.ca/pubrel/ dream. htm. Accessed January 28, 2003.
45. BARI 2D: a clinical study [web site]. Available at: http://www.bari2d. org/index.html. Accessed December 18, 2002.